logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for pharmaceutical industry professionals · Monday, July 20, 2026 · 928,124,684 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Pharmaceutical Industry News  •••  Topics  •  Countries  •  U.S. States

Stelara News Monitoring

  • Published on Jul 17, 2026

    Takeda unveils secondary endpoint data from Phase III PsO pill trials

    Takeda has released data for its plaque psoriasis (PsO) pill in key secondary endpoints in high-impact areas, supporting a route to potential approval. In two randomised, multi-centre, double-blind, Phase III trials (NCT06088043 and NCT06108544), …

    Source: Clinical Trials Arena - Pending
  • Published on Jul 16, 2026

    FDA Drug Approvals Q2 2026

    Otolaryngology  Otarmeni (lunsotogene parvec)  Lunsotogene parvec is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any …

    Source: Medscape - Neutral
  • Published on 04:21 GMT

    Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

    Key Points The healthcare giant is on track to report full-year revenue of more than $100 billion. The company raised guidance for annual revenue and earnings per share. Johnson & Johnson(NYSE: JNJ) has been a top-performing stock this year. Investors …

    Source: AOL - Neutral
  • Published on Jul 14, 2026

    Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

    Dive Brief: Privately held immunology drug developer Avere Therapeutics is seeking to go public through a reverse merger with NextCure, announcing Tuesday a transaction that will also add $320 million in new funding via a sale of shares and convertible …

    Source: BioPharma Dive - Pending
  • Published on Jul 15, 2026

    J&J tops estimates on strong medicine sales, raises full-year outlook

    Johnson & Johnson JNJ-N beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for …

    Source: The Globe and Mail - Neutral
  • Published on Jul 13, 2026

    Rationalizing Biological Drug Development: Biosimilar Science, Modality-Specific Pathways, and the Bioprocessing ...

    https://stock.adobe.com The Biosimilar Paradigm and Its Evolving Scientific Foundation Regulatory frameworks governing biological medicines have developed incrementally over several decades, influenced by accumulating experience with recombinant- …

    Source: BioProcess International - Neutral
  • Published on Jul 15, 2026

    J&J beats Wall Street estimates on strength of medicines unit

    Bengaluru: Johnson & Johnson beat ​Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales …

    Source: ETPharma.com - Pending
  • Published on Jul 15, 2026

    J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

    By Michael Erman July 15 (Reuters) – Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than ​offset erosion from older …

    Source: WNCY - Wisconsin - Pending
  • Published on Jul 19, 2026

    Why Johnson & Johnson Is a Stock You Can Own Forever

    © Mario Tama / Getty Images News via Getty Images Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a stock built to be owned for decades, not traded, because its combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth …

    Source: 24/7 Wall St. - Neutral
  • Published on Jul 9, 2026

    <![CDATA[The LOE cliff]]>

    Some of the most widely prescribed and profit‑generating biologic therapies are set to lose exclusivity over the next few years, yet only a fraction have a biosimilar competitor currently in development. Patient advocates and industry groups are pushing …

    Source: Managed Healthcare Executive - Neutral
  • Published on Jul 16, 2026

    Is Johnson & Johnson a Buy After Its Latest Earnings Report?

    On Wednesday morning, Johnson & Johnson (NYSE:JNJ) published its second-quarter earnings report, but this wasn't greeted warmly. Investors generally sold the stock, and by the end of that trading session, it was down by almost 3%. This occurred on …

    Source: The Motley Fool USA - Neutral
  • Published on Jul 2, 2026

    Judge temporarily blocks Colorado’s first-in-the-nation price cap on a prescription drug

    A federal judge has temporarily blocked Colorado’s first-in-the-nation price cap on a specific prescription drug, saying that it likely runs afoul of legal precedent and federal patent law. The ruling is a blow to Gov. Jared Polis and his administration’s …

    Source: The Colorado Sun - Center-left
  • Published on Jul 16, 2026

    I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)

    Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45 …

    Source: Seeking Alpha - Indeterminate
  • Published on Jun 26, 2026

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026

    Six new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended six medicines for approval at its June 2026 meeting. The committee recommended granting a marketing authorisation for Aujemflu (influenza virus surface antigens ( …

    Source: European Medicines Agency - Pending
  • Published on Jul 18, 2026

    3 Dividend Stocks That Have Survived Every Market Crash in July

    July tests investor conviction. From the 2011 debt-ceiling standoff to the 2022 inflation shock, summer volatility has separated durable businesses from cyclical hopefuls. Three consumer staples and healthcare giants have paid and raised dividends through …

    Source: 24/7 Wall St. - Neutral
  • Published on Jul 15, 2026

    Johnson & Johnson posted stronger-than-expected earnings and raised its full-year outlook

    Johnson & Johnson $JNJ reported second-quarter sales of $25.31 billion on Wednesday, up 6.6% from a year earlier, as strong demand for drugs in its Innovative Medicine segment helped the company top expectations and lift its full-year guidance.On a per …

    Source: Quartz - Neutral
  • Published on Jul 15, 2026

    J&J medtech miss overshadows earnings beat

    By Michael Erman and Puyaan Singh July 15 (Reuters) – Johnson & Johnson said on Wednesday that its medical device unit underperformed in the second-quarter, even as strong sales of Tremfya for autoimmune conditions and cancer treatment Darzalex helped …

    Source: KDAL - Minnesota - Pending
  • Published on Jul 15, 2026

    Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance

    Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted …

    Source: Proactive UK - Neutral
  • Published on Jul 15, 2026

    Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

    2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%* 2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90 Strong operational performance …

    Source: Investing News Network - Neutral

07 days 04:25:48

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more pharmaceuticals news or search news using your own keywords. There are 928,124,684 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country >
Pharmaceutical Industry News by U.S. State >
Pharmaceutical Industry News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 07/12/2026

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Pharmaceutical Industry Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow EIN Presswire on Facebook, LinkedIn and Substack

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2026 Newsmatics Inc. · All Rights Reserved · General Terms & Conditions · Privacy Policy · Cookie Settings

By continuing to use this site, you agree to our Terms & Conditions, last updated on September 30, 2025.